Recent Updates
Recently added Catalysts
FATE Neutral Sentiment Score: 50/100

iPSC-Derived, Off-the-Shelf anti-CD19 CAR T cells Deliver Improved Clinical Outcomes in Lupus with Reduced or No Conditioning Chemotherapy

Key Takeaway: The article discusses the use of iPSC-derived, off-the-shelf anti-CD19 CAR T cells in treating lupus. It highlights improved clinical outcomes with reduced or no conditioning chemotherapy. However, specific details about the study results or implications are not provided in the text.
Price reaction · baseline $1.65 (2025-10-24 close) · 2 other FATE headline(s) in the window, move may be shared
day 0 close
-6.1%
day 1
-9.7%
day 3 · peak
-21.8%

Market Sentiment Analysis

Full Press Release Details

• Privacy Overview
• Strictly Necessary Cookies
• 3rd Party Cookies
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
For more information about the data we collect please visit our Privacy Policy .
Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Last updated: Oct 26, 2025